Kavanagh, S, UCB Pharma, Raleigh, NC, USA
-
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
Abstract Poster PDF -
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2
Abstract Poster PDF -
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials
Abstract Poster PDF -
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Abstract Poster PDF -
SKIN The Journal of Cutaneous Medicine Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Abstract Poster PDF